Disease · MONDO_0001358

bronchial disorder

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. bronchial disorder. Diseases, record MONDO_0001358. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0001358

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: bronchial disorder; Open Targets
Open Targets ID: MONDO_0001358; Open Targets
Other names: bronchial disease, bronchospasm, bronchus disease, bronchus disease or disorder, disease of bronchus, disease or disorder of bronchus, disorder of bronchus; Open Targets
Disease Ontology: DOID:1176; Disease Ontology
MeSH: D001982; MeSH
NCI Thesaurus: C34439; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 4 of its 12 drugs, from ClinicalTrials.gov; Open Targets

Drugs12

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
AZITHROMYCIN	CHEMBL529	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
LEVALBUTEROL TARTRATE	CHEMBL3989693	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
LEVODROPROPIZINE	CHEMBL1288810	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
THEOBROMINE	CHEMBL1114	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
KETAMINE	CHEMBL742	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
SENICAPOC	CHEMBL405821	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ALBUTEROL	CHEMBL714	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
IPRATROPIUM BROMIDE	CHEMBL2134724	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
LIDOCAINE	CHEMBL79	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
MOMETASONE	CHEMBL1201404	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 12

See all 12 drugs

Targets43

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ADRB2	Beta-2 adrenergic receptor	2	Beta-2 adrenergic receptor agonist	Phase 3	https://conductscience.org/library/genes/154	Drugs and targets
GABRA1	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2554	Drugs and targets
GABRA2	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2555	Drugs and targets
GABRA3	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2556	Drugs and targets
GABRA4	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2557	Drugs and targets
GABRA5	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2558	Drugs and targets
GABRA6	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2559	Drugs and targets
GABRB1	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2560	Drugs and targets
GABRB2	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2561	Drugs and targets
GABRB3	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2562	Drugs and targets

1 to 10 of 43

See all 43 targets

Trials8

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02150499	A Study of Levalbuterol Tartrate HFA Inhalation Aerosol Metered Dose Inhaler (MDI) in Pediatric Subjects	Phase 3	18	2016-02-03	Asthma	LEVALBUTEROL TARTRATE	Its record names the disease	ClinicalTrials.gov
NCT06936761	This Study Evaluated the Safety of Awake Extubation in Children at Risk for Respiratory Events Undergoing General Anesthesia.		425		Respiratory Tract Infection	PROPOFOL, SEVOFLURANE	Its record names the disease	ClinicalTrials.gov
NCT01416480	Clinical Trial to Evaluate the Safety and Efficacy of "Theobromine Capsule" as an Antitussive in Acute Cougher	Phase 3	332		Acute Bronchitis	LEVODROPROPIZINE, THEOBROMINE	Open Targets' reading of its record	ClinicalTrials.gov
NCT04085744	A Comparison Of Local Anesthetic Agents And Steroid On Tracheal Tube Cuff	Not applicable	91		Anesthesia Intubation Complication, Intubation Complication, Sore Throat	LIDOCAINE, MOMETASONE	Its record names the disease	ClinicalTrials.gov
NCT00360464	A Trial Of Azithromycin SR For The Treatment Of Acute Bronchitis And Secondary Infection Of Chronic Respiratory Diseases	Phase 3	64		Acute Bronchitis	AZITHROMYCIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT01714401	Nebulized Bronchodilators and Cardiac Repolarization	Not applicable	50		Influence of Nebulized Bronchodilatators on Selected, Electrophysiological Parameters	ALBUTEROL, IPRATROPIUM BROMIDE	Its record names the disease	ClinicalTrials.gov
NCT03000413	Ketamine Efficacy for Acute Severe Bronchospasm in ICU: MACANUDO Trial	Phase 2/3	45		Critical Illness, Asthma, Bronchospasm	KETAMINE	Its record names the disease	ClinicalTrials.gov
NCT00861211	Safety and Efficacy Study of Oral Senicapoc on Allergen Challenge in Atopic Asthmatic Subjects	Phase 2	34		Atopic Asthma	SENICAPOC	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
Levalbuterol Tartrate HFA Inhalation Aerosol Plus Placebo HFA vs Levalbuterol Tartrate HFA Inhalation Aerosol Plus Levalbuterol: serious adverse events	0 of 9	0 of 9	18	NCT02150499

Source Trial comparisons

Papers from its trials1

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it
30242825	DERIVED	1

Source PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0001358

GET https://conductscience.org/api/diseases/v1/MONDO_0001358/targets?page=2

API reference For AI assistants